Codivir, an antiviral drug that has shown to be effective against COVID-19, was featured in a Taiwan News article. The peptide had a direct antiviral effect against SARS-CoV-2, the novel Coronavirus that causes COVID-19, according to Code Pharma. Antiviral activity against SARS-CoV-2 and other RNA viruses was demonstrated in vitro at the British virology research laboratory Virology Research Services in London.
Following the results of the phase I study, the company is starting a phase II double-blind controlled study with a larger cohort in Spain, Brazil, South Africa and Israel. CEO and founder of Code Pharma, Zyon Ayni, said: “The results obtained were unprecedented. The company is preparing for massive production to meet the global market demands”.
